2023年4月3日

分水岭multi-omics洞察力平台的信息——开发人员对于生物制药发现团队——宣布关闭1450万美元资金轮帆布与参与企业从现有投资者酸性Venture Partners和同谋企业。这一轮融资使得流域加强商业牵引,加快产品创新,并最终转变multi-omics科学家发现的药物。基因组学和multi-omics是一组技术和方法,为科学家们提供了一个前所未有的数据量和细节理解所有级别的生物活性。自从第一个人类基因组测序,科学家们一直希望将这种类型的数据变成治愈。与最近的爆炸性发展高通量实验室仪器,AI-powered分析和云计算,这场革命终于触手可及。尽管构建工具精度药物存在,他们仍然支离破碎。整合这些工具仅仅是禁止所有除了资助资助机构,需要大量的时间和资源的承诺但没有成功的保证。为了解决这个未满足的需求,流域开发了组学的长椅上,一个平台,汇集不同的工具到一个统一的云生态系统,让科学家从样本到治疗的洞察力在一天之内。组学台上为全基因组测序提供了全面的工作流程和相关的可视化,单细胞和空间转录组,表观基因组学,蛋白质组学,代谢组学,微生物测序,蛋白质折叠。和通过简单和功能之间的平衡,分水岭吸引了越来越多的用户社区的目标设计和自信和轻松地重复实验。 KEY QUOTES: “While the size and variety of data in the life sciences has grown exponentially for the past two decades, there remains a lack of centralized and collaborative platforms serving both biologists and bioinformaticians. After years of tackling tough high-performance computing and user interface challenges, we have invented new ways for any user—regardless of computational skill—to independently create, seamlessly share, and expertly customize multi-omics workflows.” — Watershed co-founder and CEO Jonathan Wang “Watershed has been executing at an incredible pace for the last three years, creating an exceptional platform that solves real-world drug discovery needs. We are excited to partner with them as they continue to break down barriers impeding biomedical discovery.” — Paul Hsiao, founding partner at Canvas Ventures, who has joined the company’s Board of Directors Trending on Pulse 2.0